|Mr. Simon Michel||Chief Exec. Officer||668.1k||N/A||1977|
|Mr. Niklaus Ramseier||Chief Financial Officer||N/A||N/A||1963|
|Mr. Frank Mengis||COO & Sr. VP of Operations||N/A||N/A||1964|
|Mr. Hans-Ulrich Lehmann||Sr. VP of Technology & CTO||N/A||N/A||1966|
|Thomas Kutt||Head of Investor Relations||N/A||N/A||N/A|
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through Ypsomed Delivery Systems and Ypsomed Diabetes Care segments. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. The company operates in Switzerland, other European countries, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Ypsomed Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.